Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Yellowhammer heightens supply fears
The majority of vet medicines used in the UK are either produced, or enter via, the EU.
NOAH and BVA express ‘no-deal’ concerns

According to a statement released by NOAH on 12 September in response to the Government’s publication of its Operation Yellowhammer document, the majority of veterinary medicines used in the UK – including the ingredients and components needed to make them – are either produced in, or enter via, the EU.
 
NOAH states: ’Our industry has been working closely with regulators, and has responded very well to concerns about supply, with detailed planning measures for all EU Exit scenarios, including no deal. These plans have involved a great deal of work and cover all aspects of supply chains from regulatory compliance and stocking levels to logistics and customs.

‘They also include, as appropriate, increasing stocks of products in the UK, changing supply routes, transferring marketing authorisations and other regulatory processes. However, in a no-deal situation there are also broader issues that could impact on availability of veterinary medicines.’

An example of this is the supply of ‘temperature-sensitive’ vaccines that have to be maintained in certain conditions. If transport is delayed and they are stuck on a lorry for hours with no power supply, those vaccines could become completely useless, and the consignment lost.

Commenting on the Government paper, Dawn Howard, NOAH chief executive, pointed out that any disruption in supplies will represent a potential risk to controlling disease and is an animal welfare issue. If preventive medicines, such as vaccines, are not available, there is a greater risk of disease in the population, including the spread of zoonotic infections.

Endorsing this position, BVA president, Simon Doherty, said: “Continued access to veterinary medicines post-Brexit is essential for safeguarding animal health and welfare, public safety and the food chain in the UK. Our concerns with regards to veterinary medicines lie with those for long-term health conditions and medicines that have a short shelf life, such as vaccines.
 
“While we don’t advise the stockpiling of medicines, we would advise animal owners to discuss the timing of any vaccinations with their vet. We would also urge pet owners whose animals are undergoing long-term treatment to seek repeat prescriptions in good time from their veterinary practice.”
 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.